Can a pill prevent dangerous platelet drops during breast cancer treatment?
NCT ID NCT07198672
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether herombopag tablets can prevent low platelet counts in 45 women with HER2-positive breast cancer who are receiving T-DM1 therapy. T-DM1 is effective but often causes low platelets, especially in Asian patients, which can force treatment delays or dose reductions. Participants will take herombopag at the start of each T-DM1 cycle to see if it keeps platelet levels safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- herombopag olamine tablets
- What this could lead to
- If it works, this could offer a way to prevent dangerous low platelet counts in HER2+ breast cancer patients on T-DM1, helping them complete their cancer therapy without delays or dose cuts.
- What could go wrong
- This is a small, early exploratory study with no control group, so results may not be definitive. The drug may not prevent low platelets effectively or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?